Van de Wiele C - Search Results

1

The potential role of quorum-sensing peptides in oncology.

Wynendaele E, Pauwels E, Van de Wiele C, Burvenich C, De Spiegeleer B. Wynendaele E, et al. Among authors: de spiegeleer b, van de wiele c. Med Hypotheses. 2012 Jun;78(6):814-7. doi: 10.1016/j.mehy.2012.03.018. Epub 2012 Apr 16. Med Hypotheses. 2012. PMID: 22513236

2

Quantitative p retreatment VOI analysis of liver metastases. (99m)Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT.

Van de Wiele C, Stellamans K, Brugman E, Mees G, De Spiegeleer B, D'Asseler Y, Beels L, Maes A. Van de Wiele C, et al. Among authors: de spiegeleer b. Nuklearmedizin. 2013;52(1):21-7. doi: 10.3413/Nukmed-0514-12-07. Epub 2013 Jan 29. Nuklearmedizin. 2013. PMID: 23358716 Clinical Trial.

3

Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review.

Van de Wiele C, De Vos F, Slegers G, Van Belle S, Dierckx RA. Van de Wiele C, et al. Among authors: van belle s, de vos f. Eur J Nucl Med. 2000 Sep;27(9):1421-33. doi: 10.1007/s002590000305. Eur J Nucl Med. 2000. PMID: 11007529 Review.

4

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, Geboes K, Peeters M. De Bruyne S, et al. Among authors: van de wiele c, van damme n. Br J Cancer. 2012 Jun 5;106(12):1926-33. doi: 10.1038/bjc.2012.184. Epub 2012 May 17. Br J Cancer. 2012. PMID: 22596235 Free PMC article. Clinical Trial.

5

99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy.

Rottey S, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van de Wiele C. Rottey S, et al. Among authors: van belle s, van de wiele c. Q J Nucl Med Mol Imaging. 2007 Jun;51(2):182-8. Q J Nucl Med Mol Imaging. 2007. PMID: 17220821 Free article.

6

Impact of FDG PET on the management of TBC treatment. A pilot study.

Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele C. Sathekge M, et al. Among authors: van de wiele c. Nuklearmedizin. 2010;49(1):35-40. doi: 10.3413/nukmed-0270. Nuklearmedizin. 2010. PMID: 20162246

7

Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within.

Kruse V, Mees G, Maes A, D'Asseler Y, Borms M, Cocquyt V, Van De Wiele C. Kruse V, et al. Among authors: van de wiele c. Q J Nucl Med Mol Imaging. 2015 Dec;59(4):462-8. Epub 2014 Apr 3. Q J Nucl Med Mol Imaging. 2015. PMID: 24695005

8

Targeting monocytes and macrophages by means of SPECT and PET.

Van De Wiele C, Sathekge M, Maes A. Van De Wiele C, et al. Q J Nucl Med Mol Imaging. 2014 Sep;58(3):269-75. Q J Nucl Med Mol Imaging. 2014. PMID: 24844256 Review.

9

CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.

Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V. Kruse V, et al. Among authors: van de wiele c. Nuklearmedizin. 2014 Aug 6;53(4):131-8. doi: 10.3413/Nukmed-0634-13-12. Nuklearmedizin. 2014. PMID: 25100557

10

Optimizing background correction when calculating differential renal function in the presence of hydroureteronephrosis using 99Tc(m)-DTPA.

Van de Wiele C, De Sadeleer C, Koole M, D'Asseler Y, Everaert K, Dierckx RA. Van de Wiele C, et al. Among authors: de sadeleer c. Nucl Med Commun. 1998 Mar;19(3):251-5. doi: 10.1097/00006231-199803000-00009. Nucl Med Commun. 1998. PMID: 9625500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters